February 18th 2025
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.